Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
V001-BCMA in Idiopathic Inflammatory Myopathies: NCT07339540 Clinical Landscape Report 2026
18 September 2026
NCT07339540 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Pembrolizumab in Melanoma, Cutaneous Malignant: NCT07349303 Clinical Landscape Report 2026
18 September 2026
NCT07349303 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
N17350 in Advanced Malignant Solid Neoplasm: NCT07339176 Clinical Landscape Report 2026
18 September 2026
NCT07339176 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Velinotamig in Systemic Lupus Erythematosus: NCT07348055 Clinical Landscape Report 2026
18 September 2026
NCT07348055 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Mucosal Melanoma: NCT07347444 Clinical Landscape Report 2026
18 September 2026
NCT07347444 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Breast Cancer: NCT07353437 Clinical Landscape Report 2026
18 September 2026
NCT07353437 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT07351487 Clinical Landscape Report 2026
18 September 2026
NCT07351487 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pucotenlimab in Mucosal Melanoma of the Head and Neck: NCT07353073 Clinical Landscape Report 2026
18 September 2026
NCT07353073 clinical landscape for Mucosal Melanoma of the Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
WGb-0301 in Idiopathic Inflammatory Myopathies: NCT07349823 Clinical Landscape Report 2026
18 September 2026
NCT07349823 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Tirzepatide in Endometrioid intraepithelial neoplasia: NCT07349641 Clinical Landscape Report 2026
18 September 2026
NCT07349641 clinical landscape for Endometrioid intraepithelial neoplasia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Butylidenephthalide in Glioblastoma, IDH-Wildtype: NCT07349693 Clinical Landscape Report 2026
18 September 2026
NCT07349693 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab govitecan-hziy in Metastatic Triple-Negative Breast Carcinoma: NCT07359404 Clinical Landscape Report 2026
18 September 2026
NCT07359404 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…